Form 4: Anika Therapeutics Director John B. Henneman III Reports Stock Transaction

Director John B. Henneman III of Anika Therapeutics reports acquisition and disposal of common stock and restricted stock units.

Summary

• On July 9, 2024, John B. Henneman III, a director of Anika Therapeutics, Inc., reported a transaction involving the company's common stock.
• Henneman acquired 5,771 shares of common stock and disposed of 35,707 shares.
• Following the reported transaction, Henneman directly owns 35,707 shares of Anika Therapeutics common stock.
• The acquired shares relate to restricted stock units (RSUs) that vest on the earlier of the 2025 annual meeting or July 9, 2025.
• Each RSU represents a contingent right to receive one share of the company's common stock.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's a standard practice for directors and officers to report such transactions.

Stakeholder Impact

• Shareholders are informed about the trading activities of a company director, contributing to transparency.

Key Dates